To evaluate the synergistic effect of PCSK9 inhibition and CD137 costimulation in tumor growth, syngeneic mouse models were created by generating subcutaneous LLC cells for tumor growth delay experiments with the PCSK9 neutralizing antibody evolocumab and the anti-mouse CD137 agonist antibody 1D8 (Figure 4A). The gene discussed is TNFRSF9; the disease is neoplasm.